Is it Apt to Retain Haemonetics Stock in Your Portfolio for Now?
HAE's Plasma franchise and NexSys PCS momentum may support growth, but heavy debt and competitive pressure remain key concerns.
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart. BCRX targets $1.8bn in revenues and $1bn in cash by 2033, leveraging best-in-class efficacy and less frequent dosing for navenibart to challenge market incumbents. Recent Q1 results showed 11% YoY Orladeyo revenue growth, robust non-GAAP profitability, and reaffirmed 2026 guidance, suggesting valuation remains attractive.
Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Haemonetics Corporation (HAE) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Investing in Haemonetics (HAE)? Don't Miss Assessing Its International Revenue Trends
Examine the evolution of Haemonetics' (HAE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.
Is the Options Market Predicting a Spike in Haemonetics Stock?
Investors need to pay close attention to GBTG stock based on the movements in the options market lately.
Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Haemonetics Corporation (HAE) Presents at Bank of America Global Healthcare Conference 2026 Transcript
HAE Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Cut
Haemonetics beats Q4 EPS and revenue estimates, shares rise 1.4%, but gross margin falls 120 basis points as the company sets its FY27 growth outlook.
Haemonetics Q4 Earnings Call Highlights
Haemonetics NYSE: HAE reported fiscal fourth-quarter revenue of $346 million, up 5% on a reported basis and 9% organically excluding CSL, as strength in its Plasma and Blood Management Technologies businesses offset continued pressure in Interventional Technologies.
Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript
Haemonetics Corporation (HAE) Q4 2026 Earnings Call Transcript
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.29 per share, beating the Zacks Consensus Estimate of $1.28 per share. This compares to earnings of $1.24 per share a year ago.
Here's Why Haemonetics (HAE) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
